Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder drug, the health regulator said on Friday.

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda, which began in 2024. This extension leverages the Beacon Platform to accelerate data-driven development of sleep biomarkers and patterns, and su...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patien...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and...

Takeda Pharmaceutical Company Limited ( TAK ) Q2 2026 Earnings Call October 30, 2025 6:00 AM EDT Company Participants Christopher David O'Reilly - Global Head of Investor Relations & Global Finance Christophe Weber - President, CEO & Representative Director Milano Furuta - CFO & Director Andrew Plump - President of Research & Development and Representative Director Teresa Bitetti - President of...

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: “Takeda's fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition ...

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules October 22, 2025 9:00 AM EDT Company Participants Zhengwei Song - Director of IR & Financial Strategy De-Chao Yu - Co-Founder, Chairman & CEO Samuel Suhua Zhang - Global Chief Business Officer Hui Zhou - Chief R&D Officer for Oncology Phuong Morrow - H...

The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.